Skip to main
KOD

KOD Stock Forecast & Price Target

KOD Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Kodiak Sciences is a promising company with a positive outlook due to the potential of its innovative ABC platform and its investigational medicines, tarcocimab tedromer, KSI-501, and KSI-101. The recent stellar data from the GLOW2 trial and the anticipated pivotal data in 3Q26, 4Q26, and 2Q27 make Kodiak a strong buy. However, there may be financing risks and competition from other big biopharma companies to keep an eye on.

Bears say

Kodiak Sciences is a pre-commercial biotechnology company with a focus on developing and commercializing transformative therapies for retinal diseases using its proprietary ABC platform. Despite the company's promising pipeline, there are potential risks surrounding future clinical data and regulatory approvals, as well as the need for additional financing. Furthermore, the company's stock price has been volatile, which is not uncommon for developmental companies in the biotechnology sector. The success of Kodiak's investigational medicines, tarcocimab tedromer (Zenkuda), KSI-501, and KSI-101, will be key factors in determining the company's future financial performance and overall success.

KOD has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kodiak Sciences Inc (KOD) Forecast

Analysts have given KOD a Buy based on their latest research and market trends.

According to 7 analysts, KOD has a Buy consensus rating as of Jul 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kodiak Sciences Inc (KOD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.